A promising drug that slows the growth of breast cancer and postpones the need for chemotherapy

A team of scientists revealed that a drug “next generation” has achieved promising results in the treatment of thousands of women from advanced breast cancer, as it slows the growth of tumors and delays the need for intense chemotherapy. The daily drug, “Kamesstrant” works to prevent the growth of cancer cells, especially in the most common type of breast cancer, which is positive for hormone receptors (HR) and negative HER-2 receptors.

The study included 3325 patients from 23 countries, which were regularly examined using liquid biopsy technique to discover genetic mutations in the DNA of cancer, especially the ESR1 boom associated with treatment resistance.

315 patients, who were proven to have a mutation in the ESR1 gene, underwent a therapeutic experiment using the “Kamesterant” drug with CDK4/6 inhibitors (inhibiting two important enzyme activity: CDK4 and CDK6, which are two protein playing a major role in organizing the cell division cycle), compared to traditional hormonal therapy with the same inhibitor.

The results showed the risk of developing the disease or death by 56% in women who took “Kamizstrant”, with an average delay in the spread of cancer up to 16 months compared to 9.2 months in the other group.

And “Kamesstrant” obtained the classification of “innovative treatment” from the American Food and Drug Administration, which facilitates its adoption, and it is underway to accelerate its adoption in the United Kingdom.

The results were presented at the American Association for Clinical Oncology (ASCO) in Chicago.